• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS NH3L AMMONIA; ENZYMATIC METHOD, AMMONIA

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS NH3L AMMONIA; ENZYMATIC METHOD, AMMONIA Back to Search Results
Catalog Number 20766682322
Device Problem High Test Results (2457)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 12/01/2017
Event Type  malfunction  
Manufacturer Narrative
The investigation is ongoing.This event occurred in (b)(6).
 
Event Description
The initial reporter received questionable nh3l ammonia results for three patients from cobas 8000 cobas c 702 module serial number (b)(4).The customer suspected an interference.Data was only provided for two of the patients.Patient 1: the specific date of this event was not known, therefore (b)(6) 2017 was used.In (b)(6) 2017, the child patient had liver failure and received a liver transplant.After surgery she had tpn (total parenteral nutrition) with smof (lipids) and numeta (a.O.Amino acids/trace elements, but not additional lipids).With the nh3l assay, high ammonia concentrations were reported, around 120 mol/l over several days.Dialysis (cvvh) was started because of kidney failure, but ammonia levels did not decrease.Six days post liver transplant the patient's the initial ammonia result 173 umol/l.The laboratory technician made a 1:1 dilution and the result was 90 umol/l.He suspected a collection error, requested a new sample, and observed exactly the same.No specific data was provided for the new sample.For a new sample on (b)(6) 2019, the initial result was 73.2 umol/l and was reported outside of the laboratory.The same sample was repeated later that day and the result was 58.0 umol/l.The same sample was repeated using nh3l ammonia gen 2 reagent and the result was 15.5 umol/l.Patient 2: on (b)(6) 2019, the nh3l result was 130.6 umol/l, but nh3l gen 2 result was 21.4 umol/l.A 1:2 dilution was performed and the result was 27.5 umol/l.On (b)(6) 2019, the nh3l result was 130.6 umol/l, but nh3l gen 2 result was 21.3 umol/l.A 1:2 dilution was performed and the result was 55 umol/l.The questionable results were reported outside of the laboratory.
 
Manufacturer Narrative
On (b)(6) 2019, the customer received questionable nh3l ammonia results for one additional patient (12 months old with liver disease).The nh3l results from the cobas c702 analyzer were 52.6 mol/l and 46.0 mol/l.The nh3l2 results from the cobas c502 analyzer were 22.7 mol/land 21.6 mol/l.It was unknown if any questionable result was reported outside of the laboratory or if the patient was adversely affected.
 
Manufacturer Narrative
Information was provided that the customer thinks there might have been a false treatment (unnecessary dialysis) based on a too high ammonia result.Additional information about the patient, treatment, and current condition was requested.However, the customer could not provide any further information other than "at least one patient (child) that was sent to another hospital".
 
Manufacturer Narrative
Additional patient information was provided: patient 1 was 3 years old (nearly 4) with methylmalonic acidemia (mma).Patient 2 was a 7 year old female with methylmalonic acidemia (mma).Patient 3 ((b)(6) 2019) was a 1 year female with hepatoblastoma, treated with extended hepatectomy.Additional nh3l ammonia results were provided for patients 1 and 2.Refer to the attachment to the medwatch.- attachment: [pt-40504_additional_patient_results.Pdf].
 
Manufacturer Narrative
The investigation did not identify a product problem.The cause of the event could not be determined.Potential drug interference can be excluded.Since many patients are treated with tpn (total parenteral nutrition), but the phenomenon occurs with individual patients only, the interference by tpn with smof (lipids) and numeta (amino acids/trace elements, but not addition lipids) could be excluded.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
NH3L AMMONIA
Type of Device
ENZYMATIC METHOD, AMMONIA
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
MDR Report Key9353289
MDR Text Key219406645
Report Number1823260-2019-04150
Device Sequence Number1
Product Code JIF
Combination Product (y/n)N
PMA/PMN Number
K972250
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Type of Report Initial,Followup,Followup,Followup,Followup
Report Date 08/24/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/21/2019
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number20766682322
Device Lot NumberASKU
Was Device Available for Evaluation? Yes
Date Manufacturer Received11/01/2019
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-